Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 08, 2022 16:30 ET
|
Shattuck Labs, Inc.
– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 – – Dosed first patient in...
Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2022 08:00 ET
|
Shattuck Labs, Inc.
- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the...
Shattuck Labs Announces Participation in Upcoming November Conferences
November 03, 2022 08:30 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
November 01, 2022 16:30 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
October 05, 2022 16:30 ET
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Announces Participation in Upcoming September Conferences
September 01, 2022 16:15 ET
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 11, 2022 07:00 ET
|
Shattuck Labs, Inc.
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3’2022 with initial combination data expected...
Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 12, 2022 07:00 ET
|
Shattuck Labs, Inc.
– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on track to begin in 2H’2022; full dose-escalation...
Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2022 16:55 ET
|
Shattuck Labs, Inc.
- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - - Butyrophilin heterodimeric fusion proteins from...
Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 17:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins...